CJC-1295 vs Copper Tripeptide-1
Head-to-head comparison of CJC-1295 and Copper Tripeptide-1 for research applications. Both peptides are studied for various research applications, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Cjc 1295 | Copper Tripeptide 1 |
|---|---|---|
| Category | Growth Hormone Secretagogue | Cosmetic Peptide |
| Mechanism | CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous growth hormone, which in turn increases IGF-1 levels. | GHK-Cu delivers copper ions to skin cells while the GHK peptide acts as a signaling molecule. |
| Evidence Rating | D — Preclinical | F — No Regulatory Activity |
| Clinical Status | Research-only / Not approved for human use | Cosmetic ingredient with clinical studies. Also studied for wound healing. |
| Safety Profile | Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief; Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) | Generally well tolerated topically; Mild irritation possible at higher concentrations |
| Route | Subcutaneous | Topical |
| Dose Range | No DAC: 100 mcg before bed daily; DAC: 1–2 mg 2–3x weekly | Serums containing 0.5–2% copper tripeptide-1 (GHK-Cu) |
| Frequency | Once daily (no DAC) or 2–3 times weekly (with DAC) | 1–2 times daily |
| Molecular Weight | No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol | N/A |
| Half-Life | No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days | N/A |
Overview
CJC-1295 and Copper Tripeptide-1 are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
CJC-1295 — Mechanism & Evidence
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.
GHK-Cu 50mg
50mg
Copper Tripeptide-1 — Mechanism & Evidence
Copper tripeptide-1 (GHK-Cu) is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine. Note: This entry focuses on the cosmetic/dermatological use of GHK-Cu. For comprehensive coverage of GHK-Cu as a wound healing and research peptide, see the dedicated GHK-Cu entry. It has demonstrated wound healing, collagen-stimulating, and anti-inflammatory properties in published studies. Among cosmetic peptides, GHK-Cu has a relatively strong evidence base, including several controlled clinical studies.
Key claims: Stimulates collagen synthesis and improves skin firmness; Promotes wound healing; Reduces photodamage signs.
Shared Research Applications
These peptides target different research areas. CJC-1295 focuses on Anti-Aging, Body Composition, while Copper Tripeptide-1 targets Anti-Aging Skincare, Wound Healing.
Safety Considerations
CJC-1295: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
Copper Tripeptide-1: Generally well tolerated topically Mild irritation possible at higher concentrations Rare allergic contact dermatitis
Shop Research Peptides
GHK-Cu 50mg
50mg
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Tesamorelin vs CJC-1295: Evidence Gaps and Data
No head-to-head trial compares tesamorelin and CJC-1295. Existing evidence is analytical, not clinical, leaving efficacy claims unsupported.
CJC-1295 and Ipamorelin: Human Evidence and Limits
This reference separates what human trials, animal models, and analytical chemistry show about CJC-1295 and ipamorelin from vendor marketing, assessing the strength of the human evidence base and combination-specific safety data.
CJC-1295 and Ipamorelin Dosage: Evidence and Risks
This reference reviews the evidence on CJC-1295 and ipamorelin dosing, distinguishing what controlled studies support from what remains speculative or vendor-derived.